The Latest

Executive Summary: Resolving the "Chicken-and-Egg" Innovation CrisisThe traditional clinical trial pathway is arguably the greatest bottleneck in modern medicine. For decades, the "Gold Standard" has been the randomized controlled trial (RCT) — a process that is notoriously slow, prohibitively expensive, and ethically complex. In the 2026 regulatory landscape, a structural solution has emerged to address the "chicken-and-egg" problem: the requirement for real-world evidence (RWE) to secure clearance, but the inability to generate that evidence without market access. By utilizing Synthetic Control Arms (SCAs) and high-fidelity RWE, manufacturers can now bypass the traditional placebo-controlled trial in specific high-impact tracks. This shift, supported by the FDA TEMPO pilot and the CMS ACCESS model, allows for faster market entry, reduced development costs, and a more ethical approach to treating severe and rare conditions.The End of the Placebo: Why the Traditional RCT is FalteringThe reliance on traditional RCTs has created a crisis of efficiency in drug and device development. Developing a new drug currently costs approximately $2.6 billion, with clinical trials accounting for up to 60% of that expenditure.The Recruitment Barrier: Nearly 80% of clinical trials fail to meet their initial enrollment projections on time. In rare diseases or specialized oncology tracks, finding a statistically significant number of patients willing to be randomized into a placebo arm is often impossible.The Ethical Dilemma: In life-threatening conditions where a standard of care already exists, or where no treatment results in rapid progression, forcing patients into a placebo arm is increasingly viewed as ethically untenable.The "Noisy" Data Problem: Traditional RCT populations are often "too clean," excluding patients with the very comorbidities (e.g., obesity, diabetes, renal stress) that define the actual real-world population.Mechanics of Synthetic Control Arms: Creating the "Digital Twin"A Synthetic Control Arm (SCA) is a virtual cohort of patients that replaces or supplements the traditional control group in a clinical trial.The Role of Digital Twins and Historical DataInstead of recruiting new patients to receive a placebo, researchers use statistical modeling to create a control group from existing data sources.Historical Clinical Trial Data: Leveraging data from thousands of previous trials (some platforms now access data from over 11 million patients) to simulate how a control group would respond to the standard of care.Real-World Data (RWD): Utilizing Electronic Health Records (EHRs), claims data, and registries to build a "Digital Twin"—a model that predicts what would happen to a specific patient if they did not receive the investigational treatment.Regulatory-Grade Accuracy: Advanced AI and machine learning are used to ensure the SCA is statistically balanced against the treatment arm, accounting for age, disease stage, and comorbidities to ensure the evidence meets the "Veracity Mandate".Regulatory Alignment: The FDA’s 2025-2026 FrameworkThe FDA has fundamentally shifted its stance on RWE, moving it from a post-market surveillance tool to a pre-market authorization catalyst.The September 2025 CGT GuidanceIn late 2025, the FDA issued landmark draft guidance for Cell and Gene Therapy (CGT) products, explicitly recommending "innovative designs" for small populations. This framework allows for:Self-Controlled Trials: Using a patient’s own baseline as their control.Externally Controlled Studies: Utilizing SCAs or historical controls to establish efficacy in single-arm trials.The TEMPO-ACCESS SynergyThe FDA TEMPO pilot (launched January 2026) provides the "Regulatory Sandbox" where this data is generated. Manufacturers can deploy devices in real-world settings—specifically within the CMS ACCESS reimbursement model—while collecting the RWE required for full authorization. This "Synergistic Loop" ensures that by the time a manufacturer submits their formal application, they already have a high-veracity dataset derived from supervised clinical use.The Business Case: 50% Faster, 40% CheaperFor Industry and Private Equity executives, the shift to SCAs is a profound "multiple expansion" event.Accelerated Timelines: By eliminating the need to recruit and monitor a physical control arm, clinical trial durations can be reduced by 50% or more.Significant Cost Reduction: Reducing the number of required participants significantly cuts the costs associated with enrollment, site monitoring, and follow-up, making "imminent-failure" or rare-disease pipelines financially viable.De-risking the Approval: Trials using SCAs often have a higher chance of success because the trial is better designed from the start, using "ground truth" data to set more realistic endpoints.Valuation Multipliers: As discussed in previous articles, a company that can prove its functional efficacy through an "audit-ready" RWE dataset moves from being a "service business" to a "tech-enabled asset," potentially doubling its valuation multiples from 8x to 15x EBITDA.Strategic Implementation: Building the Evidence PackageTransitioning to an SCA-supported model requires a disciplined approach to data architecture:Select the Right Track: Focus on the 2026 high-impact areas where the FDA and CMS have already aligned: CKM, MSK, and Behavioral Health.Engage via "Sprint" Discussions: Utilize the FDA TAP (Total Product Life Cycle Advisory Program) framework to agree on endpoints and SCA protocols within 45-day "sprint" windows.Ensure Explainability: Regulators in 2026 are wary of "black box" algorithms. Every SCA must use "Explainable AI" (XAI) to ensure the methodology is transparent and defensible during a federal audit.Leverage Circle Datasets: Use integrated datasets that capture clinical diagnosis, treatment, and functional outcomes (PROMs) in a single, unalterable record to provide the "ground truth" for the SCA.ConclusionThe 2026 Veracity Mandate has effectively ended the era of "guesswork" in clinical evidence. Bypassing the traditional RCT through Synthetic Control Arms and RWE is no longer a fringe experimental strategy; it is the new standard for efficient, ethical, and high-value medical innovation. By embracing these virtual frameworks and aligning with the TEMPO and ACCESS models, healthcare leaders can bring life-saving treatments to market faster, protect their capital efficiency, and secure a dominant position in an increasingly data-driven global economy.

The Arbitrage of VeracityIn the 2026 capital markets, a profound valuation divergence has emerged between traditional healthcare service providers and "tech-enabled assets." While the broader healthcare services sector continues to trade at disciplined multiples—typically ranging from 8x to 11x EBITDA for scaled platforms—entities that successfully transition to a technology-enabled infrastructure are commanding premiums that stretch into the 14x to 16x range. This "multiple arbitrage" is driven by more than just software margins; it is a reflection of risk mitigation. Investors are increasingly penalizing labor-dependent, "analog" service models that lack proprietary data moats, while rewarding platforms that generate high-fidelity real-world evidence (RWE) and "proven medical accuracy". For private equity sponsors and MedTech founders, the strategic priority for 2026 is the conversion of clinical operations into a recurring, tech-enabled data asset. The "Service Ceiling": Why Analog Models UnderperformThe traditional healthcare service model—whether a physician practice, a contract research organization (CRO), or a diagnostic center—is historically constrained by labor intensity and linear scaling.• Labor Dependency and Margin Erosion: In 2026, health systems face a "new structural reality" where labor costs have stabilized at a permanently higher baseline. Service businesses that cannot decouple revenue growth from headcount are seeing significant margin compression.• Retrospective Risk: Analog businesses rely on administrative proxies (claims data) which are prone to audits and "reconciliation cliffs". This creates a "valuation discount" as buyers price in the uncertainty of future federal clawbacks or denials.• Low Multiple Benchmarks: As of early 2026, multi-specialty medical practices in the $5M–$10M EBITDA range are maintaining stable but modest median multiples of approximately 8.8x EBITDA. Without a technology differentiator, these assets are viewed as essential but non-scalable utilities. The Tech-Enabled Transformation: Constructing the Data MoatA "tech-enabled asset" is defined by its ability to capture clinical "ground truth" as a byproduct of the care encounter, effectively turning a service into a proprietary data stream.The "Rule of 40+Data"In the 2026 M&A market, the "Rule of 40" (where growth rate + profit margin exceeds 40%) has been augmented by a third variable: Data Veracity.• Proprietary Moats: Platforms with clinically validated, proprietary datasets that demonstrably improve outcomes command an EV/Revenue premium 20–30% higher than their non-AI peers.• Ancillary Capture: Multiples for practices that own their ancillaries (ASCs, imaging, labs) and integrate them through a unified data loop can achieve 25–40% higher revenue multiples than those limited to professional fees.• IP-Like Resilience: When a service provider uses a technology framework to prove its functional recovery rates (e.g., through sensor-based PT or digital biomarkers), it begins to trade like a medical device or software company (10.4x to 14.4x EBITDA) rather than a service practice. De-Risking the Exit: The Impact of ACCESS and TEMPOThe 2026 regulatory environment, specifically the CMS ACCESS model and FDA TEMPO pilot, has provided a "standard of truth" that directly influences valuation multiples.Binary Compliance as Value DefenseUnder the ACCESS model, 50% of the revenue is tied to performance reconciliation. An analog business cannot prove it hit these targets without expensive manual audits, creating a "due diligence red flag" for buyers. Conversely, a tech-enabled asset with an "audit-ready" record of functional outcomes (PROMs) provides an immutable defense of its revenue, allowing buyers to pay a premium for "clean" cash flows.Accelerating the Exit WindowExit windows in 2026 remain narrow and selective.• Strategic vs. Financial Buyers: Strategic buyers (like major MedTech or Life Science firms) are currently paying 20–40% higher multiples than financial sponsors for assets that offer "workflow integration" and "proven operations leveraging real data".• Dual-Track Readiness: High-quality, data-rich assets are increasingly pursuing "dual-track" processes (IPO alongside a potential sale). The mid-December 2025 IPO of Medline ($7.26B) signaled a reopening of the market for scaled, data-driven healthcare platforms. Subsector Multiples: The 2026 DashboardInvestors are shifting capital toward subsectors where technology can "grow without adding labor".‍‍Organizations that can move from the "Multi-Specialty" bucket into the "MedTech/Digital" bucket through the use of integrated datasets (Circles) essentially unlock a 5-6 turn multiple expansion. The "Outcome Engineering" PremiumFor private equity sponsors, the "New Margin Math" of 2026 is no longer about simple roll-ups; it is about "Outcome Engineering"—designing clinical pathways to hit financial targets.1. Synergy Realization: PE firms now track "Synergy Realization" as a primary KPI. Capturing >90% of pro forma synergies requires automated, interoperable systems that link disparate practices into a single "source of truth".2. Reduced Cycle Times: AI-enabled tools that automate documentation and revenue cycle management (RCM) are reducing administrative overhead and accelerating throughput, allowing assets to sustain margins even in high-inflation environments.3. Explainable AI (XAI): As AI becomes a filter for valuation, executives must ensure their technology is "explainable." Buyers in 2026 are wary of "black box" algorithms and prioritize transparency in how clinical answers are derived. Conclusion: The Imperative for 2026The "Service Business" is a legacy architecture that is becoming increasingly difficult to defend in a high-cost, high-scrutiny economy. The transition to a "Tech-Enabled Asset" is the only viable path to multiple expansion and long-term capital efficiency. By embracing the Veracity Mandate and utilizing technology to validate every clinical signal, healthcare leaders can shift their organizational valuation from the "analog ceiling" to the "digital premium," securing a 15x EBITDA exit in an environment that prizes the certainty of the outcome above all else.

The Moment of Clarity Every transformation begins with a reckoning. For healthcare AI, that reckoning has arrived. After years of exuberant promise — diagnostic precision, predictive power, automated insight — the industry now faces a harder question: can we prove any of it?The market correction underway is not a failure of technology, but a recalibration of credibility. The gap between AI’s potential and its performance has exposed the one truth that medicine has always known: evidence must be verifiable to be trusted.From Collapse to CalibrationThe collapse of confidence in healthcare AI has forced institutions to confront the limitations of opportunistic data and opaque models. This disillusionment, though painful, is constructive.It signals a collective shift from experimentation to accountability. Hospitals are implementing data provenance frameworks. Regulators are standardizing AI validation criteria. Investors are favoring platforms that demonstrate longitudinal evidence rather than short-term performance.What looks like contraction is, in reality, calibration — the transition from unverified enthusiasm to regulated maturity.The Rise of Evidence-Grade DataThe future will not be defined by better algorithms but by evidence-grade data — datasets with known origin, stable structure, and continuous verification. Circle’s architecture operationalizes this standard:Observational Protocols capture real-world evidence in structured, interoperable form.Provenance tracking ensures every record’s lineage is auditable.Federated design allows institutions to contribute without losing control.This transforms healthcare data from anecdotal exhaust into a regulated asset class — reusable, defensible, and valuable.Operational Efficiency Through ProofFor hospitals, proof-ready data reduces compliance costs and accelerates clinical validation. For researchers, it allows reproducible studies across networks. For payers and regulators, it delivers verifiable evidence without the need for redundant auditing.The same mechanisms that make AI trustworthy also make it efficient. Verification eliminates rework. Provenance reduces friction. Trust becomes not an overhead expense, but an operational advantage. The Economic ReorderingAs verification becomes the new currency, the healthcare data economy will reorganize around credibility.Vendors with unverifiable datasets will see valuations decline.Networks with validated data architectures will attract capital and partnerships.Institutions capable of continuous compliance will set the standards others must follow.The winners of this transition will be those who treat trust as infrastructure — not as a message, but as a measurable system property.Strategic OutcomeThe AI reckoning is not an end — it’s a beginning. Medicine’s next digital chapter will not be written in code, but in proof: data that can be traced, tested, and trusted across its entire lifecycle. Circle’s model offers the blueprint — a verified data ecosystem where clinicians, innovators, and regulators operate on shared evidence rather than belief. For the first time, the industry can build intelligence that is not just powerful, but accountable. That shift — from confidence to credibility — is the real opportunity of the reckoning.

Executive Summary: Bridging the Authorization-Reimbursement ChasmIn the 2026 healthcare landscape, the primary obstacle to the adoption of Digital Therapeutics (DTx) is no longer a lack of technological innovation, but a structural "lag" in the generation of high-fidelity evidence required for payer coverage [1, 2]. Historically, DTx manufacturers have been caught between the rigors of traditional randomized controlled trials (RCTs) and the immediate need for market access. The FDA Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot, launched in late 2025 and operationalized in early 2026, represents a fundamental shift: the "Regulatory Sandbox" [2, 3]. For healthcare payers—including commercial insurers and self-insured employers—the TEMPO advantage lies in the ability to evaluate pre-authorized digital tools within a controlled environment, generating the real-world evidence (RWE) necessary to prove clinical utility and cost-effectiveness before full market scale [2, 4]. The DTx Dilemma: Why Traditional HTA Frameworks FailTraditional Health Technology Assessment (HTA) and payer evaluation frameworks were designed for "static" medical devices and pharmaceuticals [5, 6]. DTx, characterized by rapid iteration and behavioral components, often fails to fit these legacy models for several reasons:• The Evidence Hierarchy Gap: Payers typically demand multiple RCTs as the "gold standard" for evidence. However, many DTx products rely on "sham" controls that are difficult to design and often lack the longitudinal RWE needed to demonstrate a sustained reduction in the Total Cost of Care (TCOC) [5].• The Site-of-Care Blind Spot: Unlike hospital-based interventions, DTx operates in the patient’s daily environment. Traditional claims data serves as a poor proxy for engagement and physiological impact in the home [5, 7].• Sustainability and Adoption Barriers: High-profile failures of early DTx leaders have increased payer skepticism regarding the long-term ROI and patient adherence of these tools [5, 8]. The Mechanics of the TEMPO SandboxTEMPO utilizes a "risk-based enforcement" approach to allow U.S.-based manufacturers to deploy digital health devices in clinical settings before obtaining final 510(k) or De Novo marketing authorization [2, 9].Enforcement Discretion as an Evaluative ToolThe FDA exercises enforcement discretion for certain premarket and investigational device requirements, provided the device is used under clinician supervision [2, 3]. This "safe space" allows manufacturers to offer devices to participants in the CMS ACCESS model, creating a coordinated environment where clinical performance and reimbursement can be tested simultaneously [2, 10].The TAP Influence: Sprint DiscussionsTEMPO adopts the successful framework of the Total Product Life Cycle Advisory Program (TAP) [11, 12].• Iterative Sprints: Rather than waiting for a single year-end review, the FDA and manufacturers engage in "sprint" discussions—focused interactions aimed at reaching agreement on clinical endpoints and data analysis within a 45-day window [2, 11].• Early Multi-Stakeholder Input: TAP advisors facilitate early engagement between manufacturers, clinicians, and payers to ensure that the data being collected in the sandbox meets the "Insurable Integrity" standards of the 2026 market [11, 12]. Payer Advantage 1: De-risking Early Adoption through RWEThe most significant benefit for payers is the shift from "speculative coverage" to "evidence-based valuation" [4, 13].• High-Fidelity RWE: Participants in the TEMPO pilot must collect and share real-world data (RWD) on device performance [2, 14]. This data—covering adherence, symptom reporting, and physiological markers—provides payers with a "ground truth" record that far exceeds the granularity of administrative claims [1, 5].• Evaluating "Substitute Spend": By tracking patients in a TEMPO/ACCESS integrated track, payers can objectively measure whether a digital therapeutic for MSK or CKM syndrome actually reduces "Substitute Spend" (e.g., unnecessary ER visits or premature surgeries) [1, 10].• Safety and Cyber Guardrails: The sandbox approach does not bypass safety. TEMPO requires robust risk mitigation plans, cybersecurity standards, and clear patient communication, ensuring that payers do not expose their members to unvetted clinical risks [2, 9]. Payer Advantage 2: Operational Synergy with CMS ACCESSTEMPO is intentionally aligned with the four clinical tracks of the CMS ACCESS model: Early Cardio-Kidney-Metabolic (eCKM), CKM, Chronic Musculoskeletal (MSK) pain, and Behavioral Health [2, 10].By leveraging these tracks, commercial payers can align their own value-based contracts with federal standards, creating a "common language" of clinical veracity [10, 18].The Actuarial Shift: From Benchmarks to BaselinesIn the 2026 Veracity Mandate, actuarial modeling is evolving. Payers can use TEMPO-derived data to move from broad population benchmarks to individualized "baseline" tracking [1, 13].• Outcome Attainment Rates (OAR): Success is measured by the percentage of a panel that meets clinical targets relative to their own starting point [1, 10].• Explainable AI (XAI): As AI-enabled devices enter the sandbox, payers must demand explainability in the underlying algorithms to ensure that clinical decisions are defensible and free from bias [9, 17]. Strategic Recommendations for Payer Executives1. Utilize TEMPO for Formulary Defense: Before granting broad coverage to a new DTx, require that it be evaluated within a TEMPO-aligned pilot to prove functional recovery and cost-savings [5, 10].2. Incentivize Circle Datasets: Encourage providers to use "Circle" frameworks—integrated datasets that capture the clinical signal directly—to provide the RWE required for OAP reconciliation [4, 13].3. Participate in TAP Engagements: Engage with the FDA TAP advisors early in the device development cycle to define the specific clinical endpoints that will trigger "insurable" reimbursement [11, 12].4. Audit for Clinical Veracity: Move away from paying for "engagement" (PEPM) and toward paying for "attainment" (OAP). Use the sandbox data to verify that clinical results were actually achieved [1, 10]. ConclusionThe TEMPO pilot represents a rare alignment of federal regulatory speed and clinical rigor [2, 3]. For payers, it is the ultimate "evaluative sandbox": a controlled environment where the value of innovation can be proven through high-veracity real-world evidence rather than speculative marketing [4, 14]. By embracing the TEMPO advantage, healthcare leaders can de-risk their digital health portfolios, secure their margins from "Substitute Spend" leakage, and provide their members with the most effective, tech-enabled care available in the 2026 economy [2, 10].

Executive Summary: The Transition from Silos to SystemsHistorically, the management of cardiovascular disease, chronic kidney disease, and metabolic disorders such as diabetes and obesity has been conducted within clinical silos. This fragmented approach often results in conflicting treatment plans, polypharmacy, and a failure to address the physiological interdependence of these organ systems. However, the American Heart Association’s (AHA) 2024–2025 framework for Cardiovascular-Kidney-Metabolic (CKM) Syndrome has fundamentally redefined these conditions as a singular, systemic disorder. In the 2026 regulatory environment, specifically within the CMS ACCESS model, this clinical shift has been codified into a financial mandate. Managing the multi-comorbid patient now requires "Outcome Engineering"—a holistic, technology-enabled strategy that treats the heart, kidneys, and metabolic system as an integrated circuit to hit measurable targets and secure Outcome-Aligned Payments (OAPs).The Anatomy of Interdependence: The CKM Lethal TriadCKM syndrome represents a "lethal triad" of metabolic risk factors, renal dysfunction, and cardiovascular stress that affects approximately 90% of U.S. adults to some degree.The Metabolic Driver: Excess or dysfunctional adiposity and insulin resistance serve as the upstream drivers of systemic inflammation and oxidative stress.The Renal Connection: Chronic kidney disease (CKD) is no longer viewed as an isolated downstream consequence but as a central player in cardiovascular health. A decline in estimated glomerular filtration rate (eGFR) or an increase in urine albumin-creatinine ratio (uACR) serves as an early, potent signal for heart failure and atherosclerotic cardiovascular disease (ASCVD).The Cardiovascular End-State: The convergence of metabolic and renal stress leads to a 37% increase in CVD mortality for each additional CKM component present in a patient.The ACCESS Mandate: Reimbursement for Multi-System ControlStarting July 2026, the CMS ACCESS model provides a definitive payment pathway for the management of CKM patients through two specific clinical tracks: Early CKM (eCKM) and Advanced CKM.Track Mechanics and Outcome TargetsUnlike the fee-for-service (FFS) model, which pays for individual visits or laboratory tests, the ACCESS CKM tracks provide recurring payments tied to the control of the entire syndrome.eCKM Track: Focuses on pre-disease states including hypertension, dyslipidemia, and obesity. The goal is the early detection and prevention of progression.Advanced CKM Track: Focuses on patients with established diabetes, stage 3a/3b CKD, or ASCVD. Success is measured by the stability or improvement of biomarkers against the patient’s own baseline.The 50% Reconciliation: To release the full performance withhold, organizations must demonstrate that a predefined percentage of their panel has met targets such as a 10 mmHg reduction in systolic blood pressure or stable eGFR trajectories.Outcome Engineering for CKM: The Pharmacological RevolutionA critical component of managing the multi-comorbid patient in 2026 is the strategic deployment of multi-organ protective therapies. Recent clinical evidence has highlighted agents that provide "cross-system" benefits.The Role of SGLT2i and GLP-1 RAsSodium-Glucose Cotransporter-2 Inhibitors (SGLT2i): These agents have moved from diabetes medications to foundational therapies for both heart failure (HFrEF and HFpEF) and CKD, demonstrating significant efficacy in reducing cardiovascular events and slowing the decline of eGFR regardless of diabetic status.Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): Beyond weight loss, GLP-1s are now recognized for their cardioprotective and potentially nephroprotective effects, particularly in reducing the risk of stroke and major adverse cardiovascular events (MACE).Nonsteroidal Mineralocorticoid Receptor Antagonists (MRAs): Finerenone and similar agents provide a targeted pathway to reduce albuminuria and protect the kidneys from inflammatory damage without the hyperkalemia risks associated with older MRAs.An engineered care pathway sequences these interventions based on real-time data to maximize "Outcome Attainment Rates" while minimizing the "Treatment Burden" that often leads to patient non-adherence.Capturing the Signal: Remote Monitoring and Real-Time VerificationIn a value-based world, the 15-minute quarterly office visit is an insufficient data source for managing complex CKM patients. High-trust evidence must be captured as a continuous signal.The Power of Continuous BiometricsHypertension Management: Remote Patient Monitoring (RPM) has demonstrated a mean reduction in systolic blood pressure of up to 20 mmHg over six months in Medicare populations—results that far exceed those of traditional office-based care.Fluid Balance Tracking: For advanced CKM patients at risk of heart failure, digital weight scales and symptom trackers provide the early warnings needed to adjust diuretics and prevent hospitalizations, thereby reducing "Substitute Spend".HbA1c and uACR: Regular, technology-supported monitoring of glucose and kidney markers allows clinicians to titrate medications (such as SGLT2i) with surgical precision, ensuring the patient remains within the target range for ACCESS reconciliation.The Strategic Business Case: Efficiency and ValuationFor healthcare executives, the integration of CKM care is not only a clinical necessity but a financial strategic imperative.Reducing Substitute Spend: CKM patients are high utilizers of emergency and inpatient services. By engineering a pathway that prevents acute decompensation, organizations avoid the negative adjustments CMS applies for care fragmentation.Mitigating Diagnostic Error: CKM patients often present with non-specific symptoms (fatigue, shortness of breath) that can be easily misattributed. Real-time data integration reduces the 11% diagnostic error rate by providing a holistic view of the patient's physiological state.Audit-Ready Assets: The 2026 Veracity Mandate requires that every clinical claim be supported by "ground truth." Organizations that maintain high-fidelity CKM datasets—linking treatment to validated outcomes—secure their revenue from proactive federal audits and increase their valuation as tech-enabled assets.ConclusionManaging the CKM patient in 2026 requires a departure from the "organ-of-the-month" specialty model. By embracing the AHA’s CKM framework and the financial incentives of the CMS ACCESS model, healthcare leaders can provide superior, holistic care that slows disease progression and improves survival. The successful CKM practice of the future is a technology-enabled enterprise that uses high-veracity data to engineer outcomes, protect revenue, and reclaim clinical authority in an increasingly complex medical economy.